Slowly Expanding Lesions Predict 9-Year Multiple Sclerosis Disease Progression

This study provides Class III evidence that in patients with RRMS starting treatment with natalizumab or fingolimod, the proportion of SELs on brain MRI was associated with EDSS score worsening and SPMS conversion at 9-year follow-up.

Source: Neurology Neuroimmunology and Neuroinflammation - February 1, 2022 Category: Neurology Authors: Preziosa, P., Pagani, E., Meani, A., Moiola, L., Rodegher, M., Filippi, M., Rocca, M. A. Tags: MRI, Class III, Multiple sclerosis Article Source Type: research